Subject: Review of Q3 Financial Allocations

---

From: Ryan Andrews <reyeslouis@example.org>  
Sent: Monday, October 2, 2023, 9:15 AM  
To: Tina Durham <bobby14@example.org>  
Subject: Review of Q3 Financial Allocations

Hi Tina,

I hope you had a great weekend!

As we approach the end of Q3, I wanted to touch base regarding the financial allocations for our ongoing projects, particularly those related to the oncology pipeline. I noticed a few discrepancies in the budget reports, and I believe they could impact our upcoming compliance review scheduled for October 15th.

Could you please verify the figures for the recent expenditures in the R&D department? Additionally, if you have any insights on the cost variances for the clinical trials, it would be incredibly helpful. Given the strategic importance of these projects, ensuring accuracy in our financial reporting is critical.

Let me know a convenient time this week for a brief meeting. I'm available on Wednesday and Thursday after 2 PM. Alternatively, if you prefer, we can discuss this over a call. You can reach me at my direct line: (555) 123-4567.

Thank you in advance for your cooperation.

Best regards,

Ryan Andrews  
Counsellor  
Merck & Co.  
Phone: (555) 123-4567  

---

From: Tina Durham <bobby14@example.org>  
Sent: Monday, October 2, 2023, 11:47 AM  
To: Ryan Andrews <reyeslouis@example.org>  
Subject: Re: Review of Q3 Financial Allocations

Hi Ryan,

Thanks for reaching out. I did have a relaxing weekend, thank you for asking!

I’ve reviewed the budget reports, and I did notice some anomalies in the R&D figures as well. I’m glad you brought this to my attention. I’ll dive deeper into the details and cross-check with our financial systems to pinpoint the source of these discrepancies. 

Regarding the cost variances for the clinical trials, initial findings suggest they could be due to extended trial phases, but I'll confirm once I have all the data. It's crucial we get these sorted before the compliance review.

I’m free on Wednesday at 3 PM for a meeting. Does that work for you? If not, we can arrange a call at your preferred time. Let's ensure everything is aligned and ready for the review.

Looking forward to resolving this together.

Best,  
Tina Durham  
Accountant, Chartered Public Finance  
Merck & Co.  
Phone: (555) 987-6543  